Ponce Jordi, Fernandez-Gonzalez Sergi, Gil-Moreno Antonio, Coronado Pluvio J, De la Rosa Jesús, Nabais Henrique, Hernández Ginés, Taltavull Anna, Gilabert-Estelles Juan, Martínez-Román Sergio, Barahona Manel, Barahona Marc, Martínez-Maestre María Ángeles
Department of Gynecology, University Hospital of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Department of Gynecologic Oncology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Cancers (Basel). 2020 Nov 16;12(11):3387. doi: 10.3390/cancers12113387.
This retrospective analysis aimed to assess the risk factors for recurrence in patients diagnosed with early-stage cervical cancer (≤IB1 or IIA1, FIGO 2009) undergoing robot-assisted radical hysterectomy in Spain and Portugal between 2009 and 2018. A second primary objective was to audit the oncological outcomes according to quality indicators (QI) proposed by the European Society of Gynecology Oncology (ESGO). The study population included 239 women. After a median follow-up of 51 months, recurrence occurred in 26 patients (10.9%). Independent factors for recurrence were clinical tumor size > 20 mm (hazard ratio (HR) 2.37), adenocarcinoma as histological type (HR 2.51), positive pelvic lymph nodes (HR 4.83), tumor grade 2 (HR 4.99), tumor grade 3 (HR 8.06), and having not performed sentinel lymph node biopsy (SLNB) (HR 4.08). All 5 QI selected were surpassed by our results. In patients with early-stage cervical cancer undergoing robotic radical hysterectomy, clinicians should be aware that tumor grade 2 and 3, tumor size > 20 mm, adenocarcinoma, positive pelvic nodes, and lack of performance of SLNB are risk factors for recurrence. Fulfillment of QI targets of the ESGO might be considered as an objective oncological outcome indicator supporting the minimally invasive approach for early-stage cervical cancer treatment.
本回顾性分析旨在评估2009年至2018年期间在西班牙和葡萄牙接受机器人辅助根治性子宫切除术的早期宫颈癌(≤IB1或IIA1,2009年国际妇产科联盟(FIGO)分期)患者的复发危险因素。第二个主要目的是根据欧洲妇科肿瘤学会(ESGO)提出的质量指标(QI)审核肿瘤学结局。研究人群包括239名女性。中位随访51个月后,26例患者(10.9%)出现复发。复发的独立危险因素包括临床肿瘤大小>20 mm(风险比(HR)2.37)、腺癌组织学类型(HR 2.51)、盆腔淋巴结阳性(HR 4.83)、肿瘤2级(HR 4.99)、肿瘤3级(HR 8.06)以及未进行前哨淋巴结活检(SLNB)(HR 4.08)。我们的结果超过了所选的所有5项QI。对于接受机器人根治性子宫切除术的早期宫颈癌患者,临床医生应意识到肿瘤2级和3级、肿瘤大小>20 mm、腺癌、盆腔淋巴结阳性以及未进行SLNB是复发的危险因素。ESGO的QI目标达成情况可被视为支持早期宫颈癌微创治疗方法的客观肿瘤学结局指标。